Analyzing blood samples for bladder cancer biomarkers
Use of Urinary Tumor Cells and Circulating Tumor Cells (CTCs) in the Prognosis and Therapy of Patients With Bladder (BCa) and Upper Urinary Tract (UTUC) Cancer"
IRCCS San Raffaele · NCT06116396
This study is testing whether analyzing blood samples can help find important markers for bladder cancer in patients with early-stage disease to improve their treatment and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele (other) |
| Locations | 1 site (Milan) |
| Trial ID | NCT06116396 on ClinicalTrials.gov |
What this trial studies
This project focuses on understanding the role of circulating tumor cells (CTCs) in patients with bladder cancer, particularly those with non-muscle invasive bladder cancer. By collecting blood samples, the study aims to identify specific biomarkers that can help in better stratifying patients at the time of their first tumor resection. The goal is to improve prognostic capabilities and potentially reduce the need for multiple invasive treatments and assessments, thereby enhancing patient quality of life. The study involves genetic analysis of isolated CTCs to uncover valuable insights into the disease.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with urothelial neoplasia who have not yet received any therapy.
Not a fit: Patients without a history of neoplastic disease or those with genetic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for bladder cancer patients, improving outcomes and reducing unnecessary procedures.
How similar studies have performed: Other studies have shown promise in using circulating tumor cells for cancer diagnostics, suggesting a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Diagnosis of urothelial neoplasia, naive for therapy Exclusion Criteria: Absence of previous neolpastic disease or genetic diseases
Where this trial is running
Milan
- Urology Department — Milan, Italy (RECRUITING)
Study contacts
- Principal investigator: Massimo Alfano, PhD — IRCCS Ospedale San Raffaele
- Study coordinator: Massimo Alfano, PhD
- Email: alfano.massimo@hsr.it
- Phone: +39022643
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Urothelial Carcinoma